FY2026 EPS Forecast for Pharming Group Decreased by Analyst

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – Equities researchers at HC Wainwright cut their FY2026 earnings estimates for Pharming Group in a report issued on Monday, September 14th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn $0.43 per share for the year, down from their previous estimate of $0.50. HC Wainwright currently has a “Buy” rating and a $37.00 target price on the stock. The consensus estimate for Pharming Group’s current full-year earnings is $0.25 per share.

A number of other brokerages also recently issued reports on PHAR. Zacks Research downgraded shares of Pharming Group from a “hold” rating to a “strong sell” rating in a research report on Friday, July 31st. Weiss Ratings reissued a “sell (d)” rating on shares of Pharming Group in a research report on Friday, August 7th. Oppenheimer restated an “outperform” rating on shares of Pharming Group in a report on Thursday, July 30th. Finally, Canaccord Genuity Group upped their price target on Pharming Group from $37.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Three analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $38.67.

Pharming Group Trading Down 3.5%

NASDAQ PHAR opened at $10.82 on Tuesday. The business’s 50-day moving average price is $12.00 and its two-hundred day moving average price is $13.80. The company has a current ratio of 3.01, a quick ratio of 2.31 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $765.82 million, a PE ratio of 90.17 and a beta of 0.01. Pharming Group has a 12 month low of $9.62 and a 12 month high of $21.34.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, July 30th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%.

Pharming Group Company Profile

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands, focused on developing and commercializing treatments for rare diseases. The company uses its expertise in protein replacement therapies and other biotechnology platforms to address conditions with limited treatment options.

Pharming’s principal product is Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause severe swelling.